From: SSEP N20 and P25 amplitudes predict poor and good neurologic outcomes after cardiac arrest
Se(%) | Sp(%) | FPR(%) | |
---|---|---|---|
N20-baseline < 0,35 µV | 35 (31–39) | 100 (100–100) | 0 (0–0) |
N20-baseline < 0,88 µV | 50 (44–56) | 94 (92–97) | 6 (3–8) |
N20–P25 < 0,56 µV | 50 (44–56) | 100 (100–100) | 0 (0–0) |
N20–P25 < 1 µV | 66 (60–72) | 93 (90–96) | 7 (4–10) |
Status myoclonus | 56 (51–62) | 94 (92–97) | 6 (3–8) |
Day 3 NSE peak > 60 µg/ml | 25 (20–31) | 93 (90–96) | 7 (4–10) |
Malignant EEG | 50 (44–56) | 89 (85–92) | 11 (8–15) |
N20-baseline < 0,88 µV + NSE > 60 µg/ml | 36 (31–41) | 100 (100–100) | 0 (0–0) |
N20–P25 < 1 µV + NSE > 60 µg/ml | 44 (38–49) | 100 (100–100) | 0 (0–0) |
Bilaterally absent N20 SSEP | 30* (25–35) | 100 (100–100) | 0 (0–0) |
N20-baseline < 0.88 µV or N20 bilaterally absent | 47 (41–52) | 94 (92–97) | 6 (3–8) |
N20–P25 < 1 µV or N20 bilaterally absent | 58* (52–63) | 94 (92–97) | 6 (3–8) |